SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma completes acquisition of additional 13.25% stake in Adcock Ingram

14 Jul 2026 Evaluate

Natco Pharma has successfully completed acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary (Adcock Ingram), a leading South African pharmaceutical and healthcare company. 

With the completion of this transaction, Natco’s shareholding in Adcock Ingram has increased from 35.75% to 49%. The acquisition was completed through Natco Pharma South Africa Proprietary, Natco’s wholly owned subsidiary in South Africa. The transaction involved the acquisition of shares for an aggregate consideration of around ZAR 1.81 billion equivalent to around Rs 1,060 crore at the transaction exchange rate. The completion of the additional stake acquisition marks another significant milestone in Natco’s long-term Africa strategy.

Natco first acquired 35.75% in Adcock Ingram through its participation in the Adcock Ingram’s delisting process in 2025 following the announcement of a firm intention offer in July 2025, shareholder approval in October 2025 and completion of the transaction in November 2025. Pursuant to that, Natco’s Board further approved the acquisition of an additional 13.25% stake in July 2026, and the transaction has now been completed following the satisfaction of customary closing conditions and regulatory requirements.

Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).


Natco Pharma Share Price

971.85 -7.85 (-0.80%)
14-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1940.15
Dr. Reddys Labs. 1245.75
Cipla 1438.55
Zydus Lifesciences 1133.85
Lupin 2469.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: